Related Experiment Videos
[Activation of endogenous nucleases as affected by sodium arsenate and cisplatin]
Abstract:
Screening of pharmaceutical agents releasing active nucleases from inactive complexes was performed. Cisplatin and sodium arsenate were shown in vitro to have such properties. Sodium arsenate which is more expedient for the treatment of human patients was studied in vivo. It was administered to albino mice in a dose of 0.2 mg/kg once a day for 6 days. Due to the release, the activity of free serum DNAse and RNAse markedly increased (1.5-2 times). Activation of endogenic nucleases is more promising than the use of exogenic enzymes in complex therapy of viral affections and rickettsiosis.
Insights
Pharmaceutical agents like sodium arsenate can release active nucleases from inactive complexes. This in vivo study in mice showed increased DNAse and RNAse activity, suggesting potential for treating viral infections.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Pharmaceutical agents can form inactive complexes.
- Nucleases play a role in cellular processes and disease.
- Targeting nucleases is a potential therapeutic strategy.
Purpose of the Study:
- To screen pharmaceutical agents capable of releasing active nucleases.
- To investigate the in vivo effects of sodium arsenate on nuclease activity.
- To evaluate the therapeutic potential of endogenous nuclease activation.
Main Methods:
- Screening of pharmaceutical agents for nuclease-releasing properties in vitro.
- In vivo administration of sodium arsenate to albino mice (0.2 mg/kg/day for 6 days).
- Measurement of free serum DNAse and RNAse activity.
Main Results:
- Cisplatin and sodium arsenate demonstrated in vitro nuclease-releasing properties.
- Sodium arsenate administration in mice led to a 1.5-2 fold increase in serum DNAse and RNAse activity.
- Endogenous nuclease activation was observed.
Conclusions:
- Sodium arsenate is a promising agent for activating endogenous nucleases.
- Activation of endogenous nucleases is a viable therapeutic approach for viral affections and rickettsiosis.
- This strategy may be more advantageous than using exogenous enzymes in complex therapy.